Positions 51–75 of 95.
Posting this as a discussion rather than a claim: REDEFINE 1 and what CagriSema actually adds over sema alone. Compared myself to a trial mean for about six months…
the FLOW rule is doing its job and people should stop complaining. This affects how posts get sorted and removed, so it belongs in the open. The discontinuation numbers…
Posting this as a discussion rather than a claim: STEP 1 vs SURMOUNT-1 side by side, with the caveats. Compared myself to a trial mean for about six months before…
relative risk reduction sells papers, absolute risk reduction makes decisions. It is the sort of thing everyone half-believes and nobody writes down. The…
Vendor-level purity averages over time, built from independent results rather than vendor claims. Transparent methodology, open dataset.
Browse resultsPosting this as a discussion rather than a claim: SURPASS — 24 things I got wrong before I got it right. Compared myself to a trial mean for about six months before…
the FLOW rule is doing its job and people should stop complaining. Nothing about this affects the ranking maths, before anyone asks. Started keeping the trial…
new phase 3 numbers, no publication yet, calm down. It is the sort of thing everyone half-believes and nobody writes down. A confidence interval is the range of effects…
the STEP question that gets asked weekly, answered properly. Not a hot take, just something I have not seen said plainly here. Spent an evening with the appendix tables…
STEP is not what most of this community thinks it is — with the reasoning, because a rule without a reason gets ignored. Started keeping the trial identifiers straight…
the STEP thing finally clicked for me and I want to write it down. Not a hot take, just something I have not seen said plainly here. Spent an evening with the appendix…
TRIUMPH is doing more work than we give it credit for. It is the sort of thing everyone half-believes and nobody writes down. Spent an evening with the appendix tables…
Slightly embarrassed to be asking this, but: how do you actually verify SURPASS. Argued for a week about a result and then read the limitations section, which conceded…
SURPASS — 16 things I got wrong before I got it right. It is the sort of thing everyone half-believes and nobody writes down. Spent an evening with the appendix tables…
the placebo arm lost weight too. always ask by how much — a position I have arrived at slowly and would like tested. Why comparing across trials almost never works,…
number needed to treat, or i am not interested, and I am aware this is a minority view on this board. Read a press release and the publication three months apart. The…
Reference standards, analytical reagents and system-suitability material. If you are running your own method, start with a known.
Reference standardsQuestion in the title, detail here: how much of what we believe about endpoint actually comes from FLOW threads. Went looking for the registered protocol to see whether…
the FLOW rule is doing its job and people should stop complaining. Nothing about this affects the ranking maths, before anyone asks. On means, which this board treats…
The title is the argument: the endpoint advice in here is 3 years out of date. Here is the rest of it. To save the first four comments: 3 years. On means, which this…
how do you actually verify SURPASS — that is what I am asking, and I have already read the wiki twice. Started keeping the trial identifiers straight in a note file…
The one-line version is the title: write the concentration on the vial. that is the whole post. The rest is why. Intention-to-treat analyses everybody randomised…
Posting this as a discussion rather than a claim: watch where the curves separate, not just whether they do. Relative risk reduction without the baseline rate is…
the STEP thing finally clicked for me and I want to write it down. Not a hot take, just something I have not seen said plainly here. Spent an evening with the appendix…
Asking properly rather than in a comment on somebody else’s thread: why does nobody talk about SELECT. Compared myself to a trial mean for about six months before…
how much of what we believe about endpoint actually comes from SURPASS threads. I am not trying to be the "source?" guy. I would just like a source. Read a press…
SURMOUNT-4 withdrawal arm, read the appendix not the abstract. Change my mind, genuinely — I have no stake in being right about this. Started keeping the trial…
Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference